Andrew Garas1, Louise A McLean2, Cinzia R De Luca3, Peter Downie4, Maria C McCarthy3. 1. Faculty of Education - Monash University, 19 Ancora Imparo Way, Clayton, Victoria, 3800, Australia. andrew.garas@monash.edu. 2. Faculty of Education - Monash University, 19 Ancora Imparo Way, Clayton, Victoria, 3800, Australia. 3. Clinical Sciences, Murdoch Children's Research Institute, Parkville, Australia. 4. Monash Children's Hospital and Department of Paediatrics, Monash University, Clayton, Australia.
Abstract
PURPOSE: Despite survival rates greater than 90%, treatment for paediatric acute lymphoblastic leukaemia (ALL) remains challenging for families. The early post-treatment phase is an especially unique time of adjustment. The primary aim of this review was to identify and synthesise research on health-related quality of life (HRQoL) for patients up to five years post-treatment. The secondary aim was to identify if theorised risk/resistance model factors could explain any variance in reported HRQoL. METHODS: We conducted a systematic review using the PRISMA guidelines across five databases: Embase, Medline, Psychinfo, Pubmed, and Cochrane. Only studies examining HRQoL up to five years post-treatment were included. Studies were excluded if they covered periods greater than five years post-treatment or did not differentiate between patients with ALL and other cancers. After assessing the quality of each study sample size, patient characteristics, HRQoL outcomes and HRQoL correlates were extracted and summarised. RESULTS: A total of 14 studies representing 1254 paediatric patients, aged 2-18 years, were found. HRQoL findings were mixed, dependent on time since completion and comparison group. Patient HRQoL was mostly lower compared to normative data, whilst higher compared to healthy control groups, patients on treatment, and patients with other types of cancers. Lower HRQoL was also found to be associated with demographic (age and sex), family dysfunction, and treatment-related factors. CONCLUSIONS: Completing treatment signalled a significant improvement in HRQoL for patients compared to being on treatment. Overall, however, HRQoL was still significantly lower than the population during the early post-treatment period.
PURPOSE: Despite survival rates greater than 90%, treatment for paediatric acute lymphoblastic leukaemia (ALL) remains challenging for families. The early post-treatment phase is an especially unique time of adjustment. The primary aim of this review was to identify and synthesise research on health-related quality of life (HRQoL) for patients up to five years post-treatment. The secondary aim was to identify if theorised risk/resistance model factors could explain any variance in reported HRQoL. METHODS: We conducted a systematic review using the PRISMA guidelines across five databases: Embase, Medline, Psychinfo, Pubmed, and Cochrane. Only studies examining HRQoL up to five years post-treatment were included. Studies were excluded if they covered periods greater than five years post-treatment or did not differentiate between patients with ALL and other cancers. After assessing the quality of each study sample size, patient characteristics, HRQoL outcomes and HRQoL correlates were extracted and summarised. RESULTS: A total of 14 studies representing 1254 paediatric patients, aged 2-18 years, were found. HRQoL findings were mixed, dependent on time since completion and comparison group. Patient HRQoL was mostly lower compared to normative data, whilst higher compared to healthy control groups, patients on treatment, and patients with other types of cancers. Lower HRQoL was also found to be associated with demographic (age and sex), family dysfunction, and treatment-related factors. CONCLUSIONS: Completing treatment signalled a significant improvement in HRQoL for patients compared to being on treatment. Overall, however, HRQoL was still significantly lower than the population during the early post-treatment period.
Authors: Tonya M Palermo; Anna C Long; Amy S Lewandowski; Dennis Drotar; Alexandra L Quittner; Lynn S Walker Journal: J Pediatr Psychol Date: 2008-04-22
Authors: Sadhna Shankar; Leslie Robison; Meriel E M Jenney; Todd H Rockwood; Eric Wu; James Feusner; Debra Friedman; Robert L Kane; Smita Bhatia Journal: Pediatrics Date: 2005-02 Impact factor: 7.124
Authors: Claire E Wakefield; Jordana K McLoone; Phyllis Butow; Kate Lenthen; Richard J Cohn Journal: Pediatr Blood Cancer Date: 2010-12-10 Impact factor: 3.167
Authors: Hannah-Rose Mitchell; Xiaomin Lu; Regina M Myers; Lillian Sung; Lyn M Balsamo; William L Carroll; Elizabeth Raetz; Mignon L Loh; Leonard A Mattano; Naomi J Winick; Meenakshi Devidas; Stephen P Hunger; Kelly Maloney; Nina S Kadan-Lottick Journal: Int J Cancer Date: 2015-09-03 Impact factor: 7.396
Authors: Stefan Essig; Qiaozhi Li; Yan Chen; Johann Hitzler; Wendy Leisenring; Mark Greenberg; Charles Sklar; Melissa M Hudson; Gregory T Armstrong; Kevin R Krull; Joseph P Neglia; Kevin C Oeffinger; Leslie L Robison; Claudia E Kuehni; Yutaka Yasui; Paul C Nathan Journal: Lancet Oncol Date: 2014-06-19 Impact factor: 41.316
Authors: Raphaële R L van Litsenburg; Jaap Huisman; Hein Raat; Gertjan J L Kaspers; Reinoud J B J Gemke Journal: Qual Life Res Date: 2012-05-01 Impact factor: 4.147
Authors: Anna Crothers; Gabrielle M Haeusler; Monica A Slavin; Franz E Babl; Francoise Mechinaud; Robert Phillips; Heather Tapp; Bhavna Padhye; David Zeigler; Julia Clark; Thomas Walwyn; Leanne Super; Frank Alvaro; Karin Thursky; Richard De Abreu Lourenco Journal: EClinicalMedicine Date: 2021-08-20